ArticleMolecular and cellular biochemistry2026
Disulfidptosis-related gene DSTN predicts prognosis and promotes malignant progression in head and neck squamous cell carcinoma.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Head and neck squamous cell carcinoma (HNSCC) is the most common malignant tumor of the head and neck tissues. Disulfidptosis is a novel form of programmed cell death caused by disulfide stress, which mainly manifests as cytoskeleton protein and F-actin breakdown. In this study, we collected 504 HNSCC patients' data from The Cancer Genome Atlas (TCGA) database and constructed a prognostic disulfidptosis-related gene signature for HNSCC patients. Destrin (DSTN), an actin depolymerizing factor, was considered a reliable prognostic biomarker, with its high expression significantly associated with shorter overall survival (OS) and progression-free survival (PFS). Functional enrichment analysis revealed that DSTN was positively correlated with extracellular matrix (ECM)-related genes, and particularly enriched in ECM degradation pathways and matrix metalloproteinase (MMP) family members, such as MMP10 and MMP3. qPCR and Western blot results showed that knockdown of DSTN inhibited the expression of ECM-related genes MMP10 and MMP3 in HNSCC cells. Tumor immune microenvironment analysis revealed that DSTN was negatively correlated with infiltration levels of various immune cells, immune checkpoints, and tumor mutational burden (TMB). Co-culture experiment of H9 cells with HNSCC cells further demonstrated that DSTN knockdown significantly upregulated the CD274 expression in HNSCC cells. In vitro functional experiments showed that DSTN knockdown effectively inhibited HNSCC cell proliferation and migration, suppressed glucose metabolism, and blocked Wnt/β-catenin signaling pathway activation; additionally, it induced F-actin contraction, triggering disulfidptosis. In vivo xenograft experiments confirmed that DSTN knockdown significantly inhibited HNSCC tumor growth. In conclusion, this study demonstrates that DSTN is a key driver promoting the malignant progression of HNSCC; high DSTN expression indicates poor prognosis, while its downregulation exerts tumor-suppressive effects through multiple mechanisms, including inhibiting the secretion of MMPs, suppressing glucose metabolism, blocking the Wnt/β-catenin signaling pathway, and inducing disulfidptosis.
Indexed as
Identifiers
42101793What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.